Skip to main content

Table 1 Cohort demographics

From: Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers

Cohort 1    
 NC
(n = 8)
PMC
(n = 16)
PPA
(n = 13)
bvFTD
(n = 16)
Age, median years (range)a52 (24–65)53 (31–71)65 (52–79)61 (40–78)
Female, N (%)4 (50)10 (62)8 (57)6 (37)
Age at onset, median years (range)63 (50–78)59 (39–77)
Years to expected onsetb, median years (range)8 (−24,+ 3)
Mutation, N (%)
C9orf728 (50)02 (13)
GRN8 (50)1 (8)
VCP1 (6)
Cohort 2Control
(n = 18)
FTDc
(n = 13)
AD
(n = 79)
 
Age, median years (range)d81 (74–86)68 (50–83)72 (54–88) 
Female, N (%)10 (56)4 (31)49 (62) 
  1. NC Non carriers, PMC Presymptomatic mutation carriers, PPA Primary progressive aphasia, bvFTD – behavioural variant FTD, AD Alzheimer’s disease
  2. a Differences in age were found between PPA and unaffected individuals (ANOVA, p = 0.001, pairwise post hoc test PPA vs NC, p = 0.01, PPA vs PMC, p = 0.01). Differences where found between FTD as a whole group and unaffected individuals (t-test, p < 0.001)
  3. b Difference between the subjects age at sampling and the mean age at onset in their family
  4. c Clinical phenotype: 7 bvFTD and 5 SD
  5. d Differences in age were found between controls and FTD/AD (ANOVA, p < 0.001, pairwise post hoc test controls vs FTD, p < 0.001, controls vs AD, p < 0.001)